Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine-induced glutamatergic changes in healthy subjects
NCT02134951Phase 4Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- May 2014
- Primary completion
- Oct 2015
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ketamine in schizophrenia spectrum and other psychotic disorders, sponsored by New York State Psychiatric Institute. Primary endpoint: Glutamate + Glutamine (Glx) Response at Day 1. Started May 2014; status: completed.
02
Drugs
ketamine
03
Conditions
schizophrenia spectrum and other psychotic disorders
Beyond the preview
Go deeper on NCT02134951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134951.